Reclast is prescribed to prevent osteoporosis ...

FDA this week issued a warning to users Novartis osteoporosis drug Reclast created (zoledronovoyi acide), saying the drug has been shown to lead to an increase in the number of patients experiencing kidney failure. Warning only goes at this time, patients who already suffer from violations of kidney patients taking nephrotoxic drugs or diuretics with Reclast. FDA also warns that patients who have severe dehydration, taking Reclast are more likely to suffer from kidney failure. While the FDA says that such failures are rarely lasix heart failure serious complications can still be seen when using the drug. The report contained two dozen violations or kidney failure, including five deaths, reported in the safety review, published in January 2009. Reclast has been available since April 2007. So the 2009 survey 11 more Reclast related fatalities and nine injuries kidneys, were also included in these figures, each of which requires lifelong dialysis for patients. Reclast is prescribed to prevent osteoporosis in postmenopausal women, which reduces the risk of hip fractures and fractures of the spine. The drug is administered with infusions every two years and may be used to increase bone mass in men with osteoporosis. If you have suffered from side effects of Reclast Drug Administration osteoporosis is strongly recommended you seek medical advice. At the same time continue to monitor FDA announcements dates for further warnings that may arise in connection with a warning. .